S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
FORGET 99% of The Stock Market (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
FORGET 99% of The Stock Market (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
FORGET 99% of The Stock Market (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
FORGET 99% of The Stock Market (Ad)pixel
NASDAQ:ALLO

Allogene Therapeutics - ALLO Stock Forecast, Price & News

$17.25
+0.68 (+4.10%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.67
$17.49
50-Day Range
$8.07
$17.25
52-Week Range
$6.43
$27.86
Volume
1.93 million shs
Average Volume
1.66 million shs
Market Capitalization
$2.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.75

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
60.9% Upside
$27.75 Price Target
Short Interest
Bearish
28.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Allogene Therapeutics in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$271,880 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.59) to ($2.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

769th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

120th out of 175 stocks

ALLO stock logo

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics Trading Up 3.1 %

Shares of ALLO traded up $0.52 during mid-day trading on Friday, reaching $17.09. 91,706 shares of the stock traded hands, compared to its average volume of 1,596,743. Allogene Therapeutics has a 1 year low of $6.43 and a 1 year high of $27.86. The firm has a fifty day moving average price of $12.13 and a 200 day moving average price of $10.06. The company has a market cap of $2.46 billion, a price-to-earnings ratio of -7.57 and a beta of 0.56.

Allogene Therapeutics (NASDAQ:ALLO - Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.09. Allogene Therapeutics had a negative net margin of 124,571.27% and a negative return on equity of 34.73%. During the same period last year, the firm earned ($0.53) earnings per share. On average, sell-side analysts anticipate that Allogene Therapeutics will post -2.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group raised shares of Allogene Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $9.00 to $32.00 in a report on Friday, July 15th. Robert W. Baird initiated coverage on shares of Allogene Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $11.00 price objective for the company. Oppenheimer reduced their price objective on shares of Allogene Therapeutics from $40.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday. Finally, Raymond James lowered shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $27.75.

Insider Buying and Selling

In related news, CMO Rafael Amado sold 11,500 shares of the company's stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $7.40, for a total value of $85,100.00. Following the completion of the transaction, the chief marketing officer now directly owns 546,257 shares in the company, valued at $4,042,301.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Allogene Therapeutics news, Director Owen N. Witte sold 10,000 shares of the business's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $11.76, for a total value of $117,600.00. Following the completion of the sale, the director now directly owns 233,271 shares of the company's stock, valued at $2,743,266.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Rafael Amado sold 11,500 shares of the business's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $7.40, for a total transaction of $85,100.00. Following the completion of the sale, the chief marketing officer now directly owns 546,257 shares of the company's stock, valued at $4,042,301.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,500 shares of company stock worth $271,880. Corporate insiders own 26.30% of the company's stock.

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Stock News Headlines

What 4 Analyst Ratings Have To Say About Allogene Therapeutics
Allogene Therapeutics Q1 2022 Earnings Preview
Allogene Flat on Study Results
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings
8/09/2022
Today
8/13/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
308
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.75
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+60.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

Net Income
$-257,010,000.00
Net Margins
-124,571.27%
Pretax Margin
-124,571.27%

Debt

Sales & Book Value

Annual Sales
$38.49 million
Book Value
$5.58 per share

Miscellaneous

Free Float
105,986,000
Market Cap
$2.48 billion
Optionable
Not Optionable
Beta
0.56

Key Executives














ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price forecast for 2022?

14 brokerages have issued 12 month price targets for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $11.00 to $43.00. On average, they expect the company's stock price to reach $27.75 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How has Allogene Therapeutics' stock price performed in 2022?

Allogene Therapeutics' stock was trading at $14.92 at the beginning of the year. Since then, ALLO shares have increased by 15.6% and is now trading at $17.25.
View the best growth stocks for 2022 here
.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.09. Allogene Therapeutics had a negative net margin of 124,571.27% and a negative trailing twelve-month return on equity of 34.73%. During the same period in the previous year, the company earned ($0.53) earnings per share.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (3.40%), JPMorgan Chase & Co. (3.14%), FMR LLC (0.92%), Northern Trust Corp (0.52%), Cerity Partners LLC (0.42%) and Deutsche Bank AG (0.34%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $17.25.

How much money does Allogene Therapeutics make?

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $2.48 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 308 workers across the globe.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.